8月3日，Twist Bioscience盘中下跌9.51%，报86.79美元/股，成交额2343.58万美元。
消息面上，公司公布财年第三季度业绩，每股亏损0.56美元，去年同期为每股盈利0.33美元，业绩由盈转亏，且亏损幅度超出市场预期的0.51美元。营收方面，当季录得1.184亿美元，同比增长23.2%，超出分析师预期的1.145亿美元。公司同时上调全年营收指引至4.56亿至4.57亿美元，并预计第四季度营收1.23亿至1.24亿美元，均高于市场预期。尽管收入端表现强劲且上调指引，但盈利能力的显著恶化主导了市场抛售情绪。此前Evercore ISI已于7月将公司评级从"跑赢大盘"下调至"与大市持平"。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.